185 results about "Small Cell Lung Carcinoma" patented technology

PCT No. PCT/US97/11564 Sec. 371 Date Apr. 14, 1999 Sec. 102(e) Date Apr. 14, 1999 PCT Filed Jul. 8, 1997 PCT Pub. No. WO98/01132 PCT Pub. Date Jan. 15, 1998The present invention relates to specific adamantyl or adamantyl group derivative containing retinoid compounds induce apoptosis of cancer cells. These adamantyl retinoid derivatives are useful for the treatment of many cancers and solid tumors, especially androgen-independent prostate cancer, skin cancer, pancreatic carcinomas, colon cancer, melanoma, ovarian cancer, liver cancer, small cell lung carcinoma, non-small cell lung carcinoma, cervical carcinoma, brain cancer, bladder cancer, breast cancer, neuroblastoma/glioblastoma, and leukemia. Also, the invention relates to novel adamantyl or adamantyl group derivative compounds which are useful as active agents for the treatment or prevention of keratinization disorders and other dermatological conditions, and other diseases.

The invention provides modified antibodies directed against GD2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, B-cell lymphoma, renal carcinoma, retinoblastoma, and other cancers of neuroectodermal origin.

The disclosure includes a method of screening for, diagnosing or detecting non-small cell lung carcinoma or an increased likelihood of developing non-small cell lung carcinoma in a subject. The method comprises:

• • (a) determining the level of at least one biomarker in a test sample from the subject wherein the at least one biomarker is selected from the biomarkers set out in Table 2, 4A, 4B, 6 and/or 7; and
  • (b) comparing the level of the at least one biomarker in the test sample with a control;

wherein detecting a difference in the level of the at least one biomarker in the test sample compared to the control is indicative of whether the subject has or does not have non-small cell lung carcinoma or an increased likelihood of developing non-small cell lung carcinoma.

The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and ovarian cancer, as well as other types of malignancy, including brain metastases of NSCLC. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N⁷ methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents and can possess additive or super-additive effects.

The invention relates to the immunoassay medical field, in particularly provides a chemiluminescence immunoassay test kit and a preparing method thereof for pro gastrin releasing peptide (31-98). Through adopting Biotin-Streptoavidin system coated antibody, the invention can improve antibody coating efficiency, and can improve the sensitivity at the same time. The test kit provides diagnosis of small-cell lung cancer with accurate chemiluminescence test kit which has simple operation and sensitive result detecting, so as to meet the requirements in clinical diagnosis.

The invention belongs to the field of genetic engineering and phymatology, in particular to a blood serum/blood plasma miRNA marker related to non-small cell lung cancer (SCLC) prognosis and an application thereof. The marker is one or more of miR-486, miR30d, miR-1 or miR-499 and can be used for preparing an auxiliary diagnostic reagent kit for the non-SCLC prognosis or a medicine for treating the SCLC.

Disclosed are methods for detecting non-small cell lung cancer using differentially expressed genes. Furthermore, novel human genes whose expression is elevated in non-small cell lung cancer compared to no-cancerous tissues are provided. Also disclosed are methods of identifying compounds for treating and preventing non-small cell lung cancer.

The invention relates to medicine application of 20(S)-ginsenoside Rg3, in particular to application of 20(S)-ginsenoside Rg3 in preparation of medicines for treating a non-small cell lung cancer. In the invention, selecting a human non-small cell lung cancer cell strain (A549 lung adenocarcinoma, H460 large cell lung cancer and LTEP-78 lung squamous carcinoma) to be inoculated under the skin of a naked mouse, and observing the influence of the SPG-Rg3 on the non-small cell lung cancer; and carrying out CD34 immunohistochemistry staining and TUNEL immunofluorescence staining on tumor tissues, and observing the influence of the SPG-Rg3 on tumor angiogenesis and apoptosis. The inclusion proves that the 20(S)-ginsenoside Rg3 can remarkably inhibit the growth of the non-small cell lung cancer, has the action mechanism related with the promotion of the tumor apoptosis and the inhibition of the tumor angiogenesis and unobvious cooperation action when being combined with cyclophosphamide for application, and can be used for the clinical chemotherapy of the non-small cell lung cancer.

The present invention provides function of the Chlorogenic acid in small cell lung cancer treatment drug preparation. The Chlorogenic acid of the present invention has prohibiting effect on small cell lung cancer. The drug can not only substitute some part of the chemotherapy, but can also reduce the complaint reaction caused by the chemotherapy in the patients. The Chlorogenic acid is a new treatment method and choice for small cell lung cancer.

The present invention relates to markers and diagnostic reagents for the diagnosis or prognosis of lung cancer. The present invention discloses for the first time that DDX56 is significantly increasedin patients with early disease progression (= 12 months) after treatment of two major subtypes of small cell lung cancer (lung squamous cell carcinoma, lung adenocarcinoma), and that the increased expression of DDX56 significantly affects the overall survival of the patients. Therefore, DDX56 can be used as a diagnostic marker for early recurrence of lung squamous cell carcinoma or lung adenocarcinoma.

This invention relates to the medicine preparation and the gene diagnosis application, especially in non-small cell lung cancer drug targeted therapy Preparation and treatment of non-small cell lung cancer of human epidermal growth factor receptor gene detection applications. Provides many kinds of person epidermal cell growth factor acceptor (EGFR) mutant gene, preparation for Chinese non-small cell lung cancer (NSCLC) targeted therapy drug target genes, gene diagnosis using target, especially for non-small Human cell lung cancer treatment epidermal growth factor receptor gene detection of gene targets, making malignancies, particularly NSCLC gene targeting drugs and the development of diagnostic reagents have a clear role in site, thus enabling more specific targeted therapy , to carry out the individualized cancer treatment.

Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.

The invention belongs to the technical field of medicines and relates to a benzothiazole formamide compound and application thereof. The benzothiazole formamide compound comprises a derivative of the benzothiazole formamide compound and pharmaceutically applicable salt; a general molecular formula is shown in the description, wherein R1, R2 and Ar are described as claims and the description. The benzothiazole formamide compound and addition salt of the pharmaceutically applicable acid of the compound can be combined with an existing medicine or can be independently utilized as an epidermal growth factor tyrosine kinase inhibitor for treating related diseases of epidermal growth factor acceptor signal transduction disorder, such as small cell lung cancer, squamous cancer, glandular cancer, large cell lung cancer, colorectal cancer, breast cancer, ovarian cancer and renal cell carcinoma. A formula is shown in the description.

The invention discloses a blood miRNA marker related to human non-small cell lung cancer and an application of the blood miRNA marker. The marker is plasma exosome-derived miRNA-375. The invention also provides a detection reagent of the blood miRNA marker related to the human lung cancer and a kit containing the detection reagent. On the other side, the invention also provides a method for detecting the marker miRNA-375. The marker and the detection reagent thereof provided by the invention can be used for preparing the detection kit for the early prognosis and detection of the non-small cell lung cancer. Different from conventional biological markers, the exosome-derived miRNA marker can achieve a stable and minimally invasive operation, easy detection and precise quantification, and meanwhile, the sensitivity and the specificity of disease diagnosis can be greatly improved.

The invention provides a targeted nano-microbubble for treating small cell lung cancer, a preparation method and application thereof. Targeted nano-microbubbles include a lipid bimolecular shell and an inert gas wrapped inside the lipid bimolecular shell, and the anti-progastrin releasing peptide monoclonal antibody of small cell lung cancer and paclitaxel are connected to the lipid bimolecular shell, The average particle size of nano-microbubbles is 300-500nm. Preparation method: dipalmitolecithin, distearoylphosphatidylethanolamine, dipalmitophosphatidic acid and paclitaxel were completely dissolved in chloroform by film hydration method to prepare paclitaxel-containing liposomes, which are aimed at anti-progastrocytosis of small cell lung cancer The hormone-releasing peptide monoclonal antibody was opened with mercaptoethylamine, incubated with the liposome above to form a stable thioether bond, and then perfluoropropane gas was passed through, and the anti-monogastric antibody targeting small cell lung cancer was obtained by mechanical vibration. Secretin-releasing peptide monoclonal antibody targeting paclitaxel nanomicrobubbles. The targeted nanometer microbubble can be used in the preparation of medicines for treating small cell lung cancer.